Androgenetic alopecia affects roughly half of all adults by middle age, yet the pharmacological toolkit has barely expanded in decades. A comprehensive expert review published in Expert Opinion on Pharmacotherapy now maps a crowded emerging pipeline that could fundamentally change how the most common form of hair loss is treated — shifting the therapeutic model from hormonal suppression to precise follicular biology.
The review, covering literature through December 2025, identifies at least nine mechanistic categories under active investigation. Topical androgen-receptor antagonists and targeted protein degraders — specifically clascoterone and GT20029 — aim to block androgenic signaling directly at the follicle without systemic hormonal consequences. On the biologic front, two prolactin-receptor inhibitors (HMI-115 and ABS-201) represent an underappreciated pathway, given prolactin's emerging role in follicular regression. AMP-303, an injectable anagen-inducer, targets the growth-phase initiation cycle. Metabolic activators PP405 and ET-02 work on follicular energy and proliferative signaling, while the thyroid hormone receptor-β agonist KB-141 adds an endocrine dimension largely absent from current regimens. Perhaps most provocative is the inclusion of rapamycin and metformin — well-studied longevity pathway modulators — now being evaluated for their mTOR and AMPK-mediated effects on follicle stem cell activation.
What makes this review analytically valuable is its breadth as a landscape map rather than a deep trial report, which also constitutes its principal limitation — most cited agents remain in early-phase trials with modest cohort sizes and no long-term safety data. The mechanistic diversity is nonetheless striking: where current standards (minoxidil, finasteride, antiandrogens) operate through relatively blunt systemic or DHT-suppression mechanisms, these newer agents target discrete nodes in follicular biology — apoptosis prevention, stem cell dormancy, receptor degradation, and metabolic priming. For health-conscious adults monitoring longevity science, the repurposing of rapamycin and metformin into dermatology is a meaningful signal that the hair follicle is increasingly viewed as a model system for aging biology. Confirmatory Phase II/III trial data will be essential before any of these therapies can be recommended clinically.